Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.
News|Videos|July 10, 2026
Highlighting zuranolone's real-world effectiveness on postpartum depression with Joy Baker, MD
Fact checked by: Joshua Fitch, Senior Editor , Nicole Canfora Lupo
The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by day 15, helps close a gap left by trials that enrolled predominantly severe cases.
Advertisement
Advertisement
A phase 4, prospective, real-world study of zuranolone (Zurzuvae; Sage Therapeutics and Biogen) for postpartum depression (PPD) produced clinically meaningful symptom improvement across all baseline severities, findings that coauthor Joy Baker, MD, FACOG, PMH-C, C-EFM, MT(ASCP), said should increase clinician comfort in prescribing the oral treatment beyond severe disease.1,2
Related to this article
Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.
Advertisement
Advertisement